Zhang Y, Xia M, Jin K, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Molecular Cancer. 2018;17(1):45. doi:10.1186/s12943-018-0796-y.
Immunohistochemical Expression of “c-MET” in Breast Carcinomas | Open Access Macedonian Journal of Medical Sciences. Published online December 21, 2020. Accessed November 29, 2022. https://oamjms.eu/index.php/mjms/article/view/5070.
Jia L, Yang X, Tian W, Gou S, Huang W, Zhao W. Increased Expression of c-Met is Associated with Chemotherapy-Resistant Breast Cancer and Poor Clinical Outcome. Med Sci Monit. 2018;24:8239-8249. doi:10.12659/MSM.913514.
Liu Y, Yu XF, Zou J, Luo ZH. Prognostic value of c-Met in colorectal cancer: A meta-analysis. World J Gastroenterol. 2015;21(12):3706-3710. doi:10.3748/wjg.v21.i12.3706.
Zhang Z, Miao L, Wang S, et al. Study on the expression of c-Met in gastric cancer and its correlation with preoperative serum tumor markers and prognosis. World Journal of Surgical Oncology. 2022;20(1):204. doi:10.1186/s12957-022-02659-2.
Motwani M, Panchabhai S, Bar J, et al. P60.12 Prevalence of c-Met overexpression (c-Met+) and Impact of Prior Lines of Treatment on c-Met Protein Expression in NSCLC. Journal of Thoracic Oncology. 2021;16(10):S1169-S1170. doi:10.1016/j.jtho.2021.08.633.
Kim JH, Jang HJ, Kim HS, Kim BJ, Park SH. Prognostic impact of high c-Met expression in ovarian cancer: a meta-analysis. J Cancer. 2018;9(19):3427-3434. doi:10.7150/jca.26071.
An ESMO Clinical Practice Guideline Express Update recommends daraxonrasib after chemotherapy for patients with previously treated RAS G12–mutant metastatic pancreatic ductal adenocarcinoma and ECOG performance status 0 to 1 after phase 3...
An ESMO Clinical Practice Guideline Express Update recommends daraxonrasib after chemotherapy for patients with previously treated RAS G12–mutant metastatic pancreatic ductal adenocarcinoma and ECOG performance status 0 to 1 after phase 3...
Final safety and patient-reported outcome analyses from the phase 3 TROPION-Breast01 trial showed that datopotamab deruxtecan was associated with fewer grade ≥3 treatment-related adverse events and delayed deterioration in quality of life,...
Final safety and patient-reported outcome analyses from the phase 3 TROPION-Breast01 trial showed that datopotamab deruxtecan was associated with fewer grade ≥3 treatment-related adverse events and delayed deterioration in quality of life,...
Results from the phase 2 DART trial showed that concurrent and consolidative durvalumab plus definitive thoracic radiation met the prespecified 2-year progression-free survival benchmark in elderly and frail patients with locally advanced...
Results from the phase 2 DART trial showed that concurrent and consolidative durvalumab plus definitive thoracic radiation met the prespecified 2-year progression-free survival benchmark in elderly and frail patients with locally advanced...
Topline results from the phase 3 INTerpath-001 trial showed that adjuvant intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Topline results from the phase 3 INTerpath-001 trial showed that adjuvant intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Results from the phase 2 BilT-02 trial demonstrated that maintenance rucaparib plus nivolumab did not meet the prespecified progression-free survival benchmark in unselected advanced biliary tract cancer after platinum-based chemotherapy but...
Results from the phase 2 BilT-02 trial demonstrated that maintenance rucaparib plus nivolumab did not meet the prespecified progression-free survival benchmark in unselected advanced biliary tract cancer after platinum-based chemotherapy but...
Five-year results from the phase 2 ELIANA trial showed that tisagenlecleucel produced durable relapse-free and overall survival in heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic...
Five-year results from the phase 2 ELIANA trial showed that tisagenlecleucel produced durable relapse-free and overall survival in heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic...
Results from a phase 1/2 trial showed that third-generation anti-CD30 CAR T-cell therapy produced high response rates and durable disease control in patients with relapsed or refractory CD30-positive lymphoma, with longer survival observed...
Results from a phase 1/2 trial showed that third-generation anti-CD30 CAR T-cell therapy produced high response rates and durable disease control in patients with relapsed or refractory CD30-positive lymphoma, with longer survival observed...
Final results from the phase 3 COMBI-I trial showed that spartalizumab plus dabrafenib and trametinib was associated with longer overall survival than dabrafenib plus trametinib alone in BRAF V600–mutant advanced melanoma, suggesting a...
Final results from the phase 3 COMBI-I trial showed that spartalizumab plus dabrafenib and trametinib was associated with longer overall survival than dabrafenib plus trametinib alone in BRAF V600–mutant advanced melanoma, suggesting a...
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
The FDA granted accelerated approval to iberdomide plus daratumumab and hyaluronidase and dexamethasone after the regimen nearly doubled the MRD-negative complete response rate compared with daratumumab and hyaluronidase plus bortezomib and...
Results from the phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative enfortumab vedotin plus pembrolizumab improved survival and response compared with neoadjuvant cisplatin plus gemcitabine in cisplatin-eligible muscle-invasive...
Results from the phase 3 KEYNOTE-B15/EV-304 trial showed that perioperative enfortumab vedotin plus pembrolizumab improved survival and response compared with neoadjuvant cisplatin plus gemcitabine in cisplatin-eligible muscle-invasive...
